New study to measure breast milk intake in infants

Mothers worry about an exhaustive list of things; University of Otago researchers are hoping to help with one – is my baby getting enough breastmilk?

The University of Otago has been granted just over $2 million in the Emerging Researcher and Explorer Grants funding rounds.

Lisa Daniels 2022 image

Dr Lisa Daniels.

Dr Lisa Daniels, Senior Research Fellow in the Department of Medicine, will be using her almost $250,000 Emerging Researcher grant to determine how much milk a breastfeeding baby is actually receiving and how that compares to the mother's perception of supply.

"The first 1,000 days are the foundation for lifelong health and wellbeing. Although exclusive breastfeeding is recommended until around six months of age, relatively few mothers in New Zealand reach this milestone.

"Perceived insufficient milk supply is reported to be a leading cause of early cessation of breastfeeding, yet it is currently unknown whether the perception of insufficient milk supply is associated with actual low breast milk supply."

The study will include 150 mothers who are breastfeeding their 3-month-old babies and who have differing perceptions of how much milk their baby is receiving.

"To the best of my knowledge this research will be the first using the gold standard stable isotope method to assess breast milk volumes – actual breast milk supply – and its association with maternal perception of breast milk supply," Dr Daniels says.

Put simply, to assess actual breast milk supply, the mother will drink a set quantity of deuterium oxide (D2O) – more commonly known as heavy water. Saliva samples collected from both māmā and pēpi over a 14-day period will determine the amount of D2O consumed by the baby through breast milk, and therefore the amount of milk baby is receiving.

The study will not only be beneficial to health professionals working with breastfeeding mothers with milk supply concerns, if the results suggests that perception of milk supply is not related to actual milk volumes produced, it could have physical and mental health benefits for mothers.

"There are many stressors on a new mother, and reducing a concern about the ability to supply sufficient amounts of milk to her infant may contribute to improved mental health and wellbeing.

"Evidence also suggests that early breastfeeding cessation is associated with an increased risk of postpartum depression, and we know that continued breastfeeding reduces mothers' risk of breast and ovarian cancers and non-communicable diseases such as type-2-diabetes," she says.

Amber Young image

Dr Amber Young.

Dr Amber Young, of the School of Pharmacy, is also using her almost $250,000 Emerging Researcher grant to help protect hapu māmā and their pēpi, this time by identifying and developing interventions to overcome barriers to maternal immunisation and improve vaccination uptake.

"The safety and benefits of maternal immunisation are widely documented, yet maternal immunisation coverage in Aotearoa is suboptimal, with less than half of pregnant people being vaccinated against influenza (flu) and pertussis (whooping cough)," she says.

"There is also large variation across regions and ethnicities – hapū Māori are much less likely to receive maternal pertussis or influenza vaccination compared to other ethnicities. Further, whooping cough hospitalisations in the first year of life are about 2.5 times higher among Māori, mostly in the first three months of life when maternal immunisation is the only means of protection.

"However, immunisation coverage in Aotearoa is insufficient, with less than half of the pregnant population immunised. Furthermore, there are significant inequities in coverage, with wahine Māori having lower coverage rates than other ethnicities, putting Māori māmā and their pēpi at higher risk from vaccine-preventable diseases."

Barriers to maternal immunisation include costs to access services, lack of transport, mistrust of health systems and lack of appropriate information, Dr Young says.

"The aims of this study are to identify and prioritise culturally appropriate interventions to improve understanding, access, and uptake of maternal vaccination among Māori hapū māmā.

"We will engage with key stakeholders in these localities including immunisation coordinators, midwives, GPs, pharmacists, Iwi healthcare providers, community representatives and hapu Māori to prioritise interventions to address the specific needs of Māori whānau to improve maternal immunisation coverage across Aotearoa."

"Overall, this will identify culturally appropriate and relevant interventions for primary care in Aotearoa, with an emphasis on improving coverage in hapū Māori," she says.

Implementing the adapted interventions and assess their ability to improve immunisation coverage in hapū wahine will be the next project.

Deputy-Vice-Chancellor (Research and Enterprise) Professor Richard Blaikie congratulated all of the recipients.

"It's wonderful to see researchers' hard work and innovative ideas recognised nationally in this manner.

"It's particularly pleasing to see Otago continue our strong showing in the Emerging Researcher category which highlights the high calibre of early-career staff at our University. I look forward to witnessing the contributions they will make to their fields."

Explorer grants

Associate Professor Christopher Brown

Department of Biochemistry

$150,000

There is an urgent need for replacements for antibiotics. During evolution bacterial viruses have evolved to manipulate or destroy specific human pathogens. There are huge and rapidly increasing numbers of sequences from bacterial viruses in the public domain, but this wealth of data has not been able to be fully utilised. We believe that it has now become possible to mine this data for new antibiotics. In preliminary studies we have identified thousands of potential anti-bacterials – the difficulty is choosing the best ones. To select these we propose to develop novel computer methods to predict their hosts, biophysical, functional, and expression properties. If successful, this research will provide proof of principle by discovering and testing pre-clinically new anti-bacterials. It will open up a novel and flexible computational approach to transform antibiotic discovery.

Associate Professor Aniruddha Chatterjee

Department of Pathology

$150,000

Although about 90 per cent of cancer deaths are caused by metastasis, the underlying molecular events that drive it are poorly understood. This limited understanding hinders the development of effective cancer treatments. Initially thought to be driven by genetic mutations, our work indicates that epigenetic changes such as DNA methylation may be responsible for driving metastasis. Until recently it has not been possible to directly demonstrate that specific methylation changes alter metastatic potential. However, the development of precision editing tools now provides an opportunity to specifically edit epigenetic states target genes and to exclusively investigate the effect of these changes on cancer cell function. Our proposed research will further develop CRISPR/Cas technology to enable high-throughput interrogation of epigenetic drivers of metastasis. We aim to demonstrate that epigenetic mechanisms drive metastasis. This will open new avenues for understanding metastasis biology, lead to better outcome prediction, and identify new therapeutic targets to treat metastatic cancers.

Emerging researcher grants

Dr Annie Wong

Department of Medicine (University of Otago, Wellington)

$249,999

Circulating tumour DNA in hastening the diagnosis of lung cancer

Lung cancer is New Zealand's top cancer research priority as it is the leading cause of cancer-related death and disproportionately disadvantages Māori and Pacific people. We aim to improve the diagnostic process of lung cancer by replacing invasive biopsies with a blood-based test of circulating tumour DNA (ctDNA). This study plans to prove the effectiveness of a customised blood test on patients with lung cancer with known gene mutations. Development of ctDNA technology will directly benefit patients by reducing diagnostic times from months to days and identifying patients who will benefit from life-saving targeted treatment. Establishing ctDNA research collaborations nationally and internationally will benefit lung cancer outcomes as well as other cancers such as colon, breast cancer and melanoma.

Dr Kathryn Hally

Department of Surgery and Anaesthesia (University of Otago, Wellington)

$249,214

Harnessing the immune system for predicting adverse postoperative recovery

As the burden of surgery rises in Aotearoa New Zealand, so too will the incidence of postoperative morbidity and mortality. Despite its necessity, the act of surgery is associated with a profound immune response which can influence an individual's postoperative recovery. Here, we provide a framework for investigating the immune response to surgery as a functional biomarker for early detection of surgical patients at-risk of adverse postoperative recovery. This study will employ cutting-edge full-spectrum flow cytometry to interrogate the trajectory of the immune response to surgery in two distinct major surgeries (orthopaedic surgery and vascular surgery) and will utilize patient-centred tools for assessing postoperative recovery. Here, we present a streamlined workflow for immunological biomarker discovery for postoperative recovery, which may provide additive information for clinical decision-making in this context.

Dr Amber Young

School of Pharmacy

$249,998

Protecting hapū māmā and pēpi from vaccine preventable diseases

Maternal immunisation against pertussis and influenza protects hapu māmā and pēpi from infection and potentially fatal outcomes. The safety and efficacy of these vaccines are well documented. However, immunisation coverage in Aotearoa is insufficient, with less than half of the pregnant population immunised. Furthermore, there are significant inequities in coverage, with wahine Māori having lower coverage rates than other ethnicities, putting Māori māmā and their pēpi at higher risk from vaccine-preventable diseases. Barriers to maternal immunisation include costs to access services, mistrust of health systems and lack of appropriate information. We will identify and develop interventions to overcome these barriers and improve vaccination uptake for hapu māmā within localities that have significant inequities. We will engage with key stakeholders in these localities including immunisation coordinators, midwives, GPs, pharmacists, Iwi, and community representatives to prioritise interventions to address the specific needs of Māori whānau to improve maternal immunisation coverage across Aotearoa.

Dr Teodora Georgescu

Department of Anatomy

$250,000

Prolactin-mediated suppression of fever during pregnancy

/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.